SEARCH

SEARCH BY CITATION

References

  • 1
    Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-538.
  • 2
    ACMD. The Primary Prevention of Hepatitis C Among Injecting Drug Users, 2009.
  • 3
    Hepatitis C Virus Projections Working Group. Estimates and projections of the hepatitis C virus epidemic in Australia 2006. http://www.nchecr.unsw.edu.au/NCHECRweb.nsf/resources/HCVPWG2006/$file/HCVPWGRepAug06.pdf; 2006.
  • 4
    De Angelis D, Sweeting M, Ades AE, Hickman M, Hope V, Ramsay M. An evidence synthesis approach to estimating hepatitis C prevalence in England and Wales. Stat Methods Med Res 2009; 18: 361-379.
  • 5
    Vickerman P, Hickman M, May M, Kretzschmar M, Wiessing L. Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis. Addiction 2009; 105: 311-318.
  • 6
    Van Den Berg C, Smit C, Brussel GV, Coutinho R, Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007; 102: 1454-1462.
  • 7
    Turner K, Hutchinson S, Craine N, Hope V, Palmateer N, Vickerman P, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of Hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 2011; doi: 10.1111/j.1360-0443.2011.03515.x [Epub ahead of print].
  • 8
    Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction 2010; 105: 844-859.
  • 9
    Sweeting M, Hope V, Hickman M, Ncube F, Ramsay M, De Angeles D. Hepatitis C infection among injecting drug users in England and Wales 1992-2006: there and back again? Am J Epidemiol 2009; 170: 352-60.
  • 10
    Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modelling analysis of its prevention utility. J Hepatol 2011; 54: 1137-1144.
  • 11
    Martin NK, Vickerman P, Hickman M. Mathematical modelling of hepatitis C treatment for injecting drug users. J Theor Biol 2011; 274: 58-66.
  • 12
    Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007; 11: 1-224.
  • 13
    NICE. Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C. Technol Appraisal Guidance 106: National Institute for Health and Clinical Excellence; 2006.
  • 14
    Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Mühlberger N, Wright D, et al. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. J Viral Hepat 2010; 17: 34-50.
  • 15
    Wright M, Grieve R, Roberts J, Main J, HC T. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006; 10: 21.
  • 16
    Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001; 345: 211-214.
  • 17
    Foster GR. Injecting drug users with chronic hepatitis C: should they be offered antiviral therapy? Addiction 2008; 103: 1412-1413.
  • 18
    Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49: 561-573.
  • 19
    Dalgard O. Follow up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis 2005; 40: S336-S338.
  • 20
    NIH. Management of Hepatitis C. 2002. NIH Consensus Statement. In: (NIH) NIoH, editor, 2002.
  • 21
    Australian Government Department of Health and Aged Care. Schedule of pharmaceutical benefits for approved pharmacists and medical practitioners. Canberra: Department of Health and Aged Care and Medicare Australia, Pharmaceutical Benefits Scheme; 2001.
  • 22
    Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006; 13: 34-41.
  • 23
    Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon α-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004; 8: 39.
  • 24
    Grieve R, Roberts J, Wright M, Sweeting M, DeAngelis D, Rosenberg W, et al. Cost effectiveness of interferon α or peginterferon α with ribavirin for histologically mild chronic hepatitis C. Gut 2006; 55: 1332-1338.
  • 25
    Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A, et al. The cost-effectiveness of testing for hepatitis C in former injecting drug users. Health Technol Assess 2006; 2006: 32.
  • 26
    NICE. Guide to the Methods of Technology Appraisal, 2008.
  • 27
    Hickman M, Hope V, Coleman B, Parry J, Telfer M, Twigger J, et al. Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action. J Public Health 2009: 1-9.
  • 28
    Government Actuary's Department. Interim life tables 1980-82 to 2004-06: Office for National Statistics.
  • 29
    Sweeting MJ, De Angelis D, Ades AE, Hickman M. Estimating the prevalence of ex-injecting drug use in the population. Stat Methods Med Res 2009; 18: 381-395.
  • 30
    Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-β±2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004; 140: 346-355.
  • 31
    McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
  • 32
    Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-134.
  • 33
    Vickerman P, Miners A, Williams J. Assessing the cost-effectiveness of interventions linked to needle and syringe programmes for injecting drug users. In: NICE, editor. London, 2008.
  • 34
    British Medical Association. British National Formulary. 2010; 59.
  • 35
    Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.
  • 36
    Waizmann M, Ackermann G. High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin. J Subst Abuse Treat 2010; 38: 338-345.
  • 37
    Grebely J, Genoway K, Khara M, Duncan F, Viljoen M, Elliott D, et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy 2007; 18: 437-443.
  • 38
    Dietze P, Stoové M, Miller P, Kinner S, Bruno R, Alati R, et al. The self-reported personal wellbeing of a sample of Australian injecting drug users. Addiction 2010; 105: 2141-2148.
  • 39
    Kimber J, Copeland L, Hickman M, Macleod J, McKenzie J, De Angelis D, et al. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ 2010; 340: c3172.
  • 40
    Vickerman P, Hickman M, Judd A. Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study. Int J Epidemiol 2007; 36: 396-405.
  • 41
    Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, et al. Mortality among regular or dependent users of heroin and other opioids: a systemic review and meta-analysis of cohort studies. Addiction 2011; 106: 32-51.
  • 42
    Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ 2010; 341.
  • 43
    Toson B, Baker A. Life expectancy at birth: methodological options for small populations. National Statistics Methodological Series No. 33; Office for National Statistics, 2003.
  • 44
    Nordt C, Stohler R. Incidence of heroin use in Zurich, Switzerland: a treatment case register analysis. The Lancet 2006; 367( 9525): 18301834.
  • 45
    Sweeting MJ, DeAngelis D, Hickman M, Ades AE. Estimating hepatitis C prevalence in England and Wales by synthesizing evidence from multiple data sources. Assessing data conflict and model fit. Biostat 2008; 9: 715734.
  • 46
    Sutton AJ, Edmunds WJ, Sweeting MJ, Gill ON. The cost-effectiveness of screening and treatment for hepatitis C in prisons in England and Wales: a cost-utility analysis. J Viral Hepat 2008; 15797808.